Real-time enrollment status for this high risk cardiovascular disease clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 3:24 PM UTC
| NCT Number | NCT07181109 |
| Recruiting Status | Recruiting |
| Condition | High Risk Cardiovascular Disease |
| Phase | PHASE3 |
| Target Enrollment | 11,000 participants |
| Active Locations | 270 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | September 18, 2026 (3 weeks ago) |
As of October 12, 2026: Clinical trial NCT07181109 is currently recruiting participants. This phase3 study for high risk cardiovascular disease is actively seeking new participants at 270 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07181109 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 270 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07181109 was last updated 3 weeks ago (September 18, 2026). HelloStudys verifies this status automatically.